Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls

No abstract is available for this paper.

• Publication year

  2010

• Venue

  World Journal of Biological Psychiatry

• Publication date

  2010-07-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3109/15622971003758748PMID 20446881
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Is the word ‘biomarker’ being properly used by proteomics research in neuroscience?

  2010cited by this paper
• Prenatal Immune Challenge Is an Environmental Risk Factor for Brain and Behavior Change Relevant to Schizophrenia: Evidence from MRI in a Mouse Model

  2009cited by this paper
• Web Based Theoretical Protein pI, MW and 2DE Map

  2009cited by this paper
• Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia.

  2009cited by this paper
• A genome-wide association study in 574 schizophrenia trios using DNA pooling

  2009cited by this paper
• Protective role of hematopoietic prostaglandin D synthase in transient focal cerebral ischemia in mice.

  2009cited by this paper
• Cytoprotective Effect of Acetyl-l-Carnitine Evidenced by Analysis of Gene Expression in the Rat Brain

  2009cited by this paper
• Oligomer assembly of the C-terminal DISC1 domain (640-854) is controlled by self-association motifs and disease-associated polymorphism S704C.

  2009cited by this paper
• Lipocalin-prostaglandin D synthase is a critical beneficial factor in transient and permanent focal cerebral ischemia.

  2009cited by this paper
• Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy

  2009cited by this paper
• Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis

  2009cited by this paper
• Erratum: The use of ASB-14 in combination with CHAPS is the best for solubilization of human brain proteins for two-dimensional gel electrophoresis (Briefings in Functional Genomics and Proteomics (2007) vol. 6 (70-75))

  2009cited by this paper
• Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues

  2008cited by this paper
• Behavioural Alterations in Rats Following Neonatal Hypoxia and Effects of Clozapine: Implications for Schizophrenia

  2008cited by this paper
• The untiring search for the most complete proteome representation: reviewing the methods.

  2008cited by this paper
• TGFBR2 gene expression and genetic association with schizophrenia.

  2008cited by this paper
• Plasma apolipoprotein E is decreased in schizophrenia spectrum and bipolar disorder.

  2008cited by this paper
• Family‐based and case‐control studies reveal no association of lipocalin‐type prostaglandin D2 synthase with schizophrenia

  2007cited by this paper
• Divergent effects of prostaglandin receptor signaling on neuronal survival.

  2007cited by this paper
• PGD(2) DP1 receptor protects brain from ischemia-reperfusion injury.

  2007cited by this paper
• Review: Glutamate and dopamine dysregulation in schizophrenia — a synthesis and selective review

  2007cited by this paper
• CSF Metabolic and Proteomic Profiles in Patients Prodromal for Psychosis

  2007cited by this paper
• 2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia.

  2007cited by this paper
• PGD2 DP1 receptor protects brain from ischemia‐reperfusion injury

  2007cited by this paper
• The use of ASB-14 in combination with CHAPS is the best for solubilization of human brain proteins for two-dimensional gel electrophoresis.

  2007cited by this paper
• Disease Biomarkers in Cerebrospinal Fluid of Patients with First-Onset Psychosis

  2006cited by this paper
• Decreased levels of apolipoprotein A-I in plasma of schizophrenic patients

  2006cited by this paper
• Meta-analysis of association between ApoE ε4 allele and schizophrenia

  2006cited by this paper
• Meta-analysis of association between ApoE epsilon4 allele and schizophrenia.

  2006cited by this paper
• Lack of association between schizophrenia and the apolipoprotein E ε4 allele

  2005cited by this paper
• Prostaglandin D2 mediates neuronal protection via the DP1 receptor

  2005cited by this paper
• Differential changes in apolipoprotein E in schizophrenia and bipolar I disorder.

  2005cited by this paper
• Altered thalamic membrane phospholipids in schizophrenia: a postmortem study.

  2004cited by this paper
• Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress

  2004cited by this paper
• Apolipoprotein E in schizophrenia: A French association study and meta‐analysis

  2003cited by this paper
• Valproic acid down‐regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase‐1 and ‐2 in rat brain

  2003cited by this paper
• Chlorpromazine equivalent doses for the newer atypical antipsychotics.

  2003cited by this paper
• Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia.

  2003cited by this paper
• Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription

  2003cited by this paper
• Association of APOE gene with schizophrenia in Chinese: a possible risk factor in times of malnutrition.

  2003cited by this paper
• From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia?

  2003cited by this paper
• Membrane Pathology in Schizophrenia: Implication for Arachidonic Acid Signaling

  2002cited by this paper
• Apolipoprotein E genotype and schizophrenia: further negative evidence

  2002cited by this paper
• Apolipoprotein E4 inhibits, and apolipoprotein E3 promotes neurite outgrowth in cultured adult mouse cortical neurons through the low-density lipoprotein receptor-related protein.

  2002cited by this paper
• Application of cDNA microarrays to examine gene expression differences in schizophrenia.

  2001cited by this paper
• Longitudinal study of brain morphology in first episode schizophrenia.

  2001cited by this paper
• Apolipoprotein E genotype in Korean schizophrenic patients.

  2001cited by this paper
• Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia

  2001cited by this paper
• CNS synaptogenesis promoted by glia-derived cholesterol.

  2001cited by this paper
• Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients.

  2000cited by this paper
• Association Study of Apolipoprotein Eε4with Clinical Phenotype and Clozapine Response in Schizophrenia

  2000cited by this paper
• Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder

  2000cited by this paper
• Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex.

  2000cited by this paper
• Apolipoprotein E genotype in Spanish schizophrenic patients.

  2000cited by this paper
• Association study of apolipoprotein E epsilon4 with clinical phenotype and clozapine response in schizophrenia.

  2000cited by this paper
• Apolipoprotein E Genotype and Schizophrenia

  1999cited by this paper
• No association of apolipoprotein epsilon 4 allele with schizophrenia even in cognitively impaired patients.

  1998cited by this paper
• Apolipoprotein E regulatory region genotype in schizophrenia.

  1998cited by this paper
• Apolipoprotein E ε4 and clinical phenotype in schizophrenia

  1997cited by this paper
• Apolipoprotein E-ɛ4 frequency in patients with schizophrenia

  1997cited by this paper
• Apolipoprotein E genotype in schizophrenia: frequency, age of onset, and neuropathologic features

  1997cited by this paper
• Apolipoprotein E epsilon 4 and clinical phenotype in schizophrenia.

  1997cited by this paper
• Apolipoprotein E epsilon 4 and clinical phenotype in schizophrenia.

  1997cited by this paper
• Apolipoprotein E-epsilon 4 frequency in patients with schizophrenia.

  1997cited by this paper
• Human Apolipoprotein E Receptor 2 A NOVEL LIPOPROTEIN RECEPTOR OF THE LOW DENSITY LIPOPROTEIN RECEPTOR FAMILY PREDOMINANTLY EXPRESSED IN BRAIN*

  1996cited by this paper
• Lack of association between schizophrenia and the apolipoprotein E epsilon 4 allele.

  1996cited by this paper
• Human Apolipoprotein E Receptor 2

  1996cited by this paper
• Serum cholesterol and treatment-resistance in schizophrenia.

  1996cited by this paper
• Apolipoprotein E type epsilon 4 allele frequency is increased in patients with schizophrenia.

  1995cited by this paper
• Apolipoprotein E type ϵ4 allele frequency is increased in patients with schizophrenia

  1995cited by this paper
• ApoE immunoreactivity and microglial cells in Alzheimer's disease brain.

  1995cited by this paper
• The membrane hypothesis of schizophrenia.

  1994cited by this paper
• Choroid plexus calcification as a possible marker of hallucinations in schizophrenia.

  1993cited by this paper
• Positive and negative symptoms in families with schizophrenia.

  1993cited by this paper
• Increased serum phospholipase A2 activity in schizophrenia: a replication study.

  1990cited by this paper
• Apolipoprotein E: cholesterol transport protein with expanding role in cell biology.

  1988cited by this paper
• Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins.

  1987cited by this paper
• The positive and negative syndrome scale (PANSS) for schizophrenia.

  1987cited by this paper
• Covert transport dysfunction in the choroid plexus as a possible cause of schizophrenia.

  1979cited by this paper
• The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance.

  1976cited by this paper

• Targeting of inflammation and prostaglandins by nonsteroidal anti-inflammatory drugs in schizophrenia: A narrative review.

  2025cites this paper
• Characterizing defective lipid metabolism in the lateral septum of mice treated with olanzapine: implications for its side effects

  2024cites this paper
• Glycoproteomics in Cerebrospinal Fluid Reveals Brain-Specific Glycosylation Changes

  2023cites this paper
• The Importance of Cerebrospinal Fluid Investigation in First-episode Psychosis

  2023cites this paper
• Brain Lipids and Lipid Droplet Dysregulation in Alzheimer’s Disease and Neuropsychiatric Disorders

  2023cites this paper
• Lower levels of soluble β-amyloid precursor protein, but not β-amyloid, in the frontal cortex in schizophrenia.

  2023cites this paper
• The Proteomic Architecture of Schizophrenia Cerebral Organoids Reveals Alterations in GWAS and Neuronal Development Factors

  2021cites this paper
• Association between clinical symptoms and apolipoprotein A1 or apolipoprotein B levels is regulated by apolipoprotein E variant rs429358 in patients with chronic schizophrenia

  2021cites this paper
• Association between cognitive impairment and apolipoprotein A1 or apolipoprotein B levels is regulated by apolipoprotein E variant rs429358 in patients with chronic schizophrenia

  2021cites this paper
• The Variants at APOA1 and APOA4 Contribute to the Susceptibility of Schizophrenia With Inhibiting mRNA Expression in Peripheral Blood Leukocytes

  2021cites this paper
• The proteomic architecture of schizophrenia iPSC-derived cerebral organoids reveals alterations in GWAS and neuronal development factors

  2021cites this paper
• Decreased serum apolipoprotein A4 as a potential peripheral biomarker for patients with schizophrenia.

  2021cites this paper
• Human CNS barrier-forming organoids with cerebrospinal fluid production

  2020cites this paper
• Thyroid Hormone Distributor Proteins During Development in Vertebrates

  2019cites this paper
• Protein Biomarkers in Major Depressive Disorder: An Update.

  2019cites this paper
• ApoE elevation is associated with the persistence of psychotic experiences from age 12 to age 18: Evidence from the ALSPAC birth cohort.

  2019cites this paper
• Mass spectrometry identification of potential biomarker proteins in the 150-kD electrophoretic band in patients with schizophrenia

  2018cites this paper
• Insights into the human brain proteome: Disclosing the biological meaning of protein networks in cerebrospinal fluid

  2017cites this paper
• Circulating biomarkers in schizophrenia : a proteomics perspective REVIEW

  2017cites this paper
• Altered apolipoprotein C expression in association with cognition impairments and hippocampus volume in schizophrenia and bipolar disorder

  2017cites this paper
• Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms

  2017influential citation
• Expanding the cerebrospinal fluid endopeptidome

  2017cites this paper
• Schizophrenia: A review of potential biomarkers.

  2017cites this paper
• Hypothesis-Driven Proteomic Data-Analysis of Plasma from Subjects in the At-Risk Mental State

  2017cites this paper
• Revisiting the genetics of APOE

  2017cites this paper
• Proteomics Research in Schizophrenia

  2016influential citation
• Neuroproteomic profiling of human body fluids

  2016cites this paper
• Proteomics insight into psychiatric disorders: an update on biological fluid biomarkers

  2016cites this paper
• Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia

  2015cites this paper
• Molecular Substrates of Schizophrenia: Homeostatic Signaling to Connectivity

  2015cites this paper
• The proteome of schizophrenia

  2015cites this paper
• Proteomic Characterization of the Brain and Cerebrospinal Fluid of Schizophrenia Patients

  2014cites this paper
• Proteomics, metabolomics, and protein interactomics in the characterization of the molecular features of major depressive disorder

  2014cites this paper
• Biomarkers in major depressive disorder: the role of mass spectrometry.

  2014cites this paper
• APOA-I: A Possible Novel Biomarker for Metabolic Side Effects in First Episode Schizophrenia

  2014cites this paper
• Metabolic, hormonal and stress-related molecular changes in post-mortem pituitary glands from schizophrenia subjects

  2013cites this paper
• Biomedical Involvements of Low-Abundance Proteins

  2013cites this paper
• Recent advances in quantitative neuroproteomics.

  2013cites this paper
• Proteomic biomarkers for psychiatric disorders: a progress update.

  2012cites this paper
• Proteomic approaches to unravel the complexity of

  2012cites this paper
• Protein phosphorylation patterns in serum from schizophrenia patients and healthy controls.

  2012cites this paper
• Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?

  2012cites this paper
• Translational strategies to schizophrenia from a proteomic perspective

  2012cites this paper
• Identification of a blood-based biological signature in subjects with psychiatric disorders prior to clinical manifestation

  2012cites this paper
• Proteomic approaches to unravel the complexity of schizophrenia

  2012cites this paper
• Large-scale analyses of schizophrenia proteome

  2012cites this paper
• Potential biomarkers in psychiatry: focus on the cholesterol system

  2012cites this paper
• What Does Proteomics Tell Us About Schizophrenia

  2011cites this paper
• Neuroglialpharmacology: white matter pathophysiologies and psychiatric treatments.

  2011cites this paper
• Cerebrospinal fluid diagnostics in first-episode schizophrenia

  2011cites this paper
• Proteomic technologies for biomarker studies in psychiatry: advances and needs.

  2011cites this paper
• Quantitative proteomics for investigating psychiatric disorders

  2011cites this paper
• Translating potential biomarker candidates for schizophrenia and depression to animal models of psychiatric disorders

  2011cites this paper
• The need for phosphoproteomic approaches in psychiatric research.

  2011cites this paper
• Prion protein-induced proteome alterations in sporadic Creutzfeldt-Jakob disease and in SH-SY 5 Y cell culture model

  2010cites this paper
• Comment on: Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls

  2010cites this paper